NEW YORK, USA and MELBOURNE, Australia, 30 July, 2024 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic-assisted psychotherapies, is pleased to announce that it has completed participant dosing in the IHL-42X Bioavailability/Bioequivalence (BA/BE) clinical trial. IHL-42X comprises two drugs, dronabinol…
AbbVie and Richter partner for neuropsychiatric treatments
The agreement focuses on the discovery, co-development and licensing of new targets that could address neuropsychiatric conditions. Credit: wavebreakmedia/Shutterstock. AbbVie has entered a collaboration with
October 25, 2024